MedPath

Hainan Huluwa Pharmaceutical Group Co., Ltd.

Hainan Huluwa Pharmaceutical Group Co., Ltd. logo
🇨🇳China
Ownership
Public, Subsidiary
Established
2005-06-22
Employees
1K
Market Cap
-
Website
http://www.huluwayaoye.com
Introduction

The company takes “Healthy China Baby” as its corporate mission, protects the healthy growth of Chinese children, and is committed to building a national brand of Chinese children's medicine. The company is a group enterprise headquartered in Haikou. It was restructured in 2008 and listed on the main board of the Shanghai Stock Exchange in July 2020. It is the first company listed on the main board in Hainan since the announcement of the overall plan for the construction of the Hainan Free Trade Port. The company has been deeply involved in the pharmaceutical manufacturing industry for many years, focusing on the field of children's medicine. It actively builds a full range of child health industry chains around the child's life cycle, covering various fields such as children's medicine, children's health food, health food, specialty food and medical devices. The company currently has a matrix of four major brands: “Hulu Wa”, “Hulu Dad”, “Hulu Mom”, and “Hulu Family”, covering pediatric product lines, adult product lines, women's product lines and health product lines to meet all aspects of market needs. Corporate honors: In June 2018, Huluwa Pharmaceutical won the title of “VIP Strategic Cooperation Enterprise” by the China Pharmaceutical Business Association; in March 2018, Huluwa Pharmaceutical won the “Brand Leadership Award” at the China Brand Pharmacy Business Summit; in December 2017, Huluwa Pharmaceutical won the honorary title of “Big Country Brand”. It has won honors such as “Leading Force China Pharmaceutical High Quality Development Achievement Enterprise”, China's National Pharmaceutical Excellent Brand Enterprise, China Pharmaceutical Industry's Most Popular Brand Enterprise, Retail Pharmacy's Most Popular Brand Enterprise, etc., and won many industry honors such as “2022 China Pharmacy Chain Most Cooperative Value Brand Award” and China Pharmaceutical's “2022 Chinese Pharmaceutical Brand List Award”. It has won honors such as Star Club's “Most Popular Star Item in Retail Pharmacies” and Sipuhui's “2023 Brand Top List”.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

211

NMPA:211

Drug Approvals

Ibuprofen Ardinine Granules

Product Name
精氨酸布洛芬颗粒
Approval Number
国药准字H20253894
Approval Date
Apr 15, 2025
NMPA

Calcitriol Soft Capsules

Product Name
骨化三醇软胶囊
Approval Number
国药准字H20253474
Approval Date
Feb 25, 2025
NMPA

Esomeprazole Sodium for Injection

Product Name
注射用艾司奥美拉唑钠
Approval Number
国药准字H20253143
Approval Date
Jan 14, 2025
NMPA

Esomeprazole Sodium for Injection

Product Name
注射用艾司奥美拉唑钠
Approval Number
国药准字H20253142
Approval Date
Jan 14, 2025
NMPA

Salbutamol Sulfate Inhalation Solution

Product Name
吸入用硫酸沙丁胺醇溶液
Approval Number
国药准字H20253018
Approval Date
Jan 2, 2025
NMPA

Oseltamivir Phosphate Capsules

Product Name
磷酸奥司他韦胶囊
Approval Number
国药准字H20249291
Approval Date
Nov 5, 2024
NMPA

Argatroban Injection

Product Name
阿加曲班注射液
Approval Number
国药准字H20249222
Approval Date
Oct 29, 2024
NMPA

Ceftezo1e Sodium for Injection

Product Name
注射用头孢替唑钠
Approval Number
国药准字H20094045
Approval Date
Oct 7, 2024
NMPA

Acetylcysteine Solution for Inhalation

Product Name
吸入用乙酰半胱氨酸溶液
Approval Number
国药准字H20244705
Approval Date
Aug 20, 2024
NMPA

Sodium Gluconate

Product Name
葡萄糖酸钠
Approval Number
国药准字H20060355
Approval Date
Jul 15, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 22
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.